What do mathematical models tell us about the emergence and spread of drug-resistant HIV?

Current Opinion in HIV and AIDS

Volumn 6, Issue 2, 2011, Pages 131-140

  Baggaley, Rebecca F ^a   Powers, Kimberly A ^b   Boily, Marie Claude ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IL   (United States)

Author keywords

Antiretroviral; HIV; Mathematical modeling; Microbicides; Pre exposure prophylaxis; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; MICROBICIDE;

ARTICLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MATHEMATICAL MODEL; PRIORITY JOURNAL; RISK REDUCTION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MODELS, THEORETICAL; UNITED STATES;

EID: 79951770159     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328343ad03     Document Type: Article

References (42)

1. Baggaley RF, Ferguson NM, Garnett GP. The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol 2005; 2:9.
2. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006; 3:e124.
3. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med 2001; 7:1016-1020. (Pubitemid 32937381)
4. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-654. (Pubitemid 30070912)
5. Nagelkerke NJ, Jha P, de Vlas SJ, et al. Modelling HIV/AIDS epidemics in Botswana and India: impact of interventions to prevent transmission. Bull World Health Organ 2002; 80:89-96. (Pubitemid 34205095)
6. Bhunu CP, Garira W, Magombedze G. Mathematical analysis of a two strain HIV/AIDS model with antiretroviral treatment. Acta Biotheor 2009; 57:361-381.
7. Hoare A, Kerr SJ, Ruxrungtham K, et al. Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. PLoS One 2010; 5:e10981.
8. Marks AJ, Pillay D, McLean AR. The effect of intrinsic stochasticity on transmitted HIV drug resistance patterns. J Theor Biol 2010; 262:1-13.
9. Smith? RJ, Okano JT, Kahn JS, et al. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science 2010; 327:697-701.
10. Westreich D, Eron J, Behets F, et al. Survival in women exposed to singledose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model. J Infect Dis 2007; 195:837-846. (Pubitemid 46363929)
11. Supervie V, Garcia-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A 2010; 107:12381-12386.
12. Abbas UL, Hood G, Wetzel A, Mellors JW. Emergence and spread of HIV drug resistance arising from roll out of antiretroviral preexposure prophylaxis (PrEP). Microbicides M2010 Conference, May 22-25. Pittsburgh, Pennsylvania, USA [Abstract 199]; 2010.
13. Wilson DP, Coplan PM, Wainberg MA, Blower SM. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci U S A 2008; 105:9835-9840. (Pubitemid 352031386)
14. Dimitrov DT, Masse B, Boily MC. Who will benefit from a wide-scale introduction of vaginal microbicides in developing countries? Stat Commun Infect Dis 2010; 2:Art4.
15. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13 (Suppl 2):1-13. (Pubitemid 352019085)
16. Zaric GS, Brandeau ML, Bayoumi AM, Owens DK. The effects of protease inhibitors on the spread of HIV and the development of drug-resistance HIV strains: a simulation study. Simulation 1998; 71:262-275. (Pubitemid 128499292)
17. Tchetgen E, Kaplan EH, Friedland GH. Public health consequences of screening patients for adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26:118-129. (Pubitemid 32224182)
18. Vardavas R, Blower S. The emergence of HIV transmitted resistance in Botswana: 'when will the WHO detection threshold be exceeded?'. PLoS One 2007; 2:e152.
19. Gadhamsetty S, Dixit NM. Estimating frequencies of minority nevirapineresistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model. J Virol 2010; 84:10230-10240.
20. McLean AR, Nowak MA. Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV. AIDS 1992; 6:71-79.
21. Ribeiro RM, Bonhoeffer S, Nowak MA. The frequency of resistant mutant virus before antiviral therapy. AIDS 1998; 12:461-465. (Pubitemid 28116154)
22. Walensky RP, Weinstein MC, Yazdanpanah Y, et al. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS 2007; 21:973-982. (Pubitemid 46691098)
23. Holmes CB, Zheng H, Martinson NA, et al. Optimizing treatment for HIVinfected South African women exposed to single-dose nevirapine: balancing efficacy and cost. Clin Infect Dis 2006; 42:1772-1780. (Pubitemid 43839446)
24. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and costeffectiveness. Clin Infect Dis 2009; 48:806-815.
25. van de Vijver DA, Derdelinckx I, Boucher CA. Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of pre-exposure prophylaxis among young women in Zimbabwe. J Infect Dis 2009; 199:1310-1317.
26. Pinkerton SD, Holtgrave DR, Bloom FR. Cost-effectiveness of postexposure prophylaxis following sexual exposure to HIV. AIDS 1998; 12:1067-1078. (Pubitemid 28276975)
27. Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis 2004; 39:395-401. (Pubitemid 39050489)
28. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010; 24:729-735.
29. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
30. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929. (Pubitemid 30177052)
31. Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591-601. (Pubitemid 351650540)
32. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-1153. (Pubitemid 32378686)
33. Nijhuis M, Schuurman R, de Jong D, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999; 13:2349-2359.
34. Derdelinckx I, Wainberg MA, Lange JM, et al. Criteria for drugs used in preexposure prophylaxis trials against HIV infection. PLoS Med 2006; 3:e454.
35. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007; 2:e27.
36. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
37. Michael NL. Oral preexposure prophylaxis for HIV: another arrow in the quiver? N Engl J Med 2010; 363:2663-2665.
38. Goudsmit J, De Ronde A, Ho DD, Perelson AS. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J Virol 1996; 70:5662-5664. (Pubitemid 26240747)
39. Leigh Brown AJ, Frost SD, Mathews WC, et al. Transmission fitness of drugresistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003; 187:683-686. (Pubitemid 36250034)
40. Vickerman P, Watts C, Delany S, et al. The importance of context: model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sex Transm Dis 2006; 33:397-405. (Pubitemid 43833029)
41. Bennett DE, Myatt M, Bertagnolio S, et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 (Suppl 2):25-36. (Pubitemid 352019087)
42. Dodd PJ, White PJ, Garnett GP. Notions of synergy for combinations of interventions against infectious diseases in heterogeneously mixing populations. Math Biosci 2010; 227:94-104.